ArticleGastroenterology & hepatology2025
Remote Patient Monitoring and Connected Technologies in Inflammatory Bowel Disease.
Article in Gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remote patient monitoring (RPM) has emerged as a valuable complement to traditional in-person clinical assessments, particularly since the COVID-19 pandemic. RPM encompasses a wide range of tools and technologies that enable the longitudinal collection of biometric, behavioral, and biochemical data outside the conventional clinic setting. These programs have been successfully integrated across several medical subspecialties, such as cardiology, endocrinology, and psychiatry, where the availability of real-time data has facilitated timely evaluation and management of chronic conditions. Building on these successes, the field of inflammatory bowel disease (IBD) has begun adopting RPM and connected health technologies to enhance both access to and quality of care. These innovations include the integration of point-of-care testing for conventional biomarkers, the development of novel biomarkers from other biospecimens (eg, mucus and sweat), and the advent of passive physiologic monitoring aimed at predicting and preventing disease relapses. This article examines current literature on RPM across chronic diseases, explores its emerging applications in IBD, and presents key barriers hindering its broader implementation.
Indexed as
Identifiers
41647469PMC12872267What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.